Latest Commercial Readiness News

Cleo Diagnostics has expanded its ovarian cancer biomarker panel from five to eight markers, enhancing test reliability and gearing up for FDA submission. A manufacturing deal is imminent, setting the stage for commercial rollout.

Nexsen Limited has successfully completed a pivotal FDA Pre-Submission meeting for its StrepSure® diagnostic, significantly reducing regulatory risks and advancing its entry into the large US maternal health market.

Provaris Energy reported a 59% increase in its half-year loss to $2.09 million, driven by higher project development costs amid progress in hydrogen and carbon capture technologies. The company raised over $3.5 million in capital and is advancing key milestones for its hydrogen shipping and liquid CO2 tank projects.

Paradigm Biopharmaceuticals has drawn down US$5 million from its Convertible Note Facility to fund the next phase of its global Phase 3 trial for knee osteoarthritis treatment, marking a key step as patient recruitment nears 50%.

Island Pharmaceuticals has raised $9 million to advance its antiviral drug Galidesivir through the FDA’s Animal Rule pathway, targeting inclusion in the US Strategic National Stockpile for biodefense viruses.

1414 Degrees has achieved a key milestone with its SiNTL silicon anode material reaching 500 mAh/g, matching current commercial standards ahead of schedule and setting sights on 600 mAh/g within a year.

Audio Pixels Holdings Limited reported a $7.2 million loss for the half-year ending June 2025, while making significant strides in refining its MEMS digital loudspeaker fabrication process and securing a $6 million loan facility.

Audio Pixels has validated a major technical milestone for its digital MEMS speaker array and raised $1.25 million through convertible notes, while securing a $6 million funding commitment to support ongoing development amid continued ASX trading suspension.

Impact Minerals reports significant advancements in its High Purity Alumina projects, a strategic collaboration with US battery innovator C4V, and renewed exploration activities in NSW’s Broken Hill region.

Neurizon Therapeutics has cleared a major regulatory hurdle with the FDA lifting the clinical hold on its lead drug NUZ-001 and secured a comprehensive $33 million funding package to advance its pivotal ALS trial.

Iondrive Limited has marked a pivotal shift from development to commercialisation of its IONSolv™ technology, securing $4 million to target the US e-waste market and commissioning its pilot plant to refine critical minerals.

First Graphene and UK manufacturer FP McCann have successfully produced the first batch of graphene-enhanced concrete roof tiles, marking a significant step toward low-carbon, high-performance construction materials in the UK housing sector.